In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics’ SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability


• Animal study shows effective protection of mitochondria against oxidative damage and reduced susceptibility to plaque in advanced atherosclerosis after treatment with SOD2 mRNA nanoparticles based on Altamira’s SemaPhore™ technology
• Data presented at American Heart Association Annual Scientific Sessions Chicago 2022 earlier this month

HAMILTON, BERMUDA / ACCESSWIRE / Nov. 22, 2022 / Altamira Therapeutics (“Altamira” or the “Company”) (NASDAQ:CYTO), a company focused on developing therapies that address important unmet medical needs, today announced the presentation of animal data generated by a research group for atherosclerosis at the University of Michigan School of Medicine (Ann Arbor, MI) showing effective mRNA delivery and protective effects in arteries with its SemaPhore™ delivery technology.

The data was presented earlier this month at the prestigious American Heart Association Annual Scientific Sessions Chicago 2022.

The research group tested the delivery of Superoxide Dismutase 2 (SOD2) mRNA with Altamira’s peptide-based SemaPhore nanoparticles to boost SOD2 expression in advanced atherosclerotic plaque cells in a mouse model. SOD2 is one of the most important antioxidant defense systems against free radicals, but it is known to be reduced in inflammatory conditions such as atherosclerosis.

The group hypothesized that increasing SOD2 expression would protect mitochondria from oxidative damage and preserve plaque stability. Atherosclerosis is a chronic inflammatory disease of the arteries, in which plaque forms on the walls, and is the underlying cause of about 50% of all deaths in westernized society. Erosion or rupture of advanced atherosclerotic plaque is the leading cause of atherosclerosis complications such as heart attack and stroke.

Treatment of mice by systemic administration of SOD2 mRNA nanoparticles resulted in markedly increased levels of SOD2 mRNA and mitochondrial SOD2 in plaque macrophages (p<0.01), and higher local SOD activity, resulting in lower levels of mitochondrial and cellular reactive oxygen species (ROS). ) and improved mitochondrial function. After only four weeks of intermittent (2x/wk) iv mRNA therapy, mice treated with SOD2 mRNA showed 25% fewer inflammatory macrophages (p<0.01) and 98% more smooth muscle cells (p<0.001) in plaques and plaque caps , which was associated with reduced plaque vulnerability (p<0.05) compared to control. The research group concluded, "The use of nanoparticle-based mRNA therapeutics to modulate plaque morphology has great potential in the prevention and treatment of atherosclerosis complications."

Samuel Wickline, MD, Chief Scientific Officer of Altamira, a co-author of the study, suggested that: “The ability to systemically deliver potent mRNA therapies to inflammatory pathologies such as atherosclerosis provides the basis for controlled regulation of harmful reactive oxidant species. in this and other disease states.”

About SemaPhore
SemaPhore is a versatile platform for safe and effective delivery of mRNA (messenger ribonucleic acid) into target cells. It is based on a proprietary 21 amino acid peptide that can involve any type of RNA in rapid self-assembly into a polyplex. The polyplex has a size, charge, and other physical characteristics that allow it to escape hepatic clearance and thus reach target tissues other than the liver. SemaPhore protects the RNA payload from degradation in the circulation and allows for rapid cellular uptake while enabling pH-dependent nucleotide endosomal escape and cytoplasmic release. Effective mRNA delivery and positive treatment outcomes have been demonstrated in several mouse disease models, including osteoarthritis (WNT16), atherosclerosis (p27Kip1), and aortic aneurysm (SOD2).

About Altamira Therapeutics
Altamira Therapeutics (NASDAQ:CYTO) is committed to developing therapies that address important unmet medical needs. The company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne allergens and, if approved, viruses (Bentrio™; commercial ) or for the treatment of vertigo (AM-125; Phase 2) and the development of therapies for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). It was founded in 2003 and is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit:

Forward-Looking Statements
This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements relating to future operational, financial or business performance or the strategies or expectations of Altamira Therapeutics. In some cases, you can identify these statements by forward-looking words such as “may”, “could”, “will”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, ” predicts”, “projects”, “potential”, “outlooks” or “continuing”, or the negation of these terms or other similar terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated in these statements. These risks and uncertainties include, but are not limited to, the completion of the initial sale of 90% of Zilentin, the exercise by Zilentin of its option to purchase additional legacy assets, the achievement by Altamira of the milestones set forth in the option agreement , Altamira’s ability to complete a divestment transaction of Bentrio, the approval and timing of the commercialization of AM-301, Altamira Therapeutics’ need for and ability to raise substantial additional financing to continue development of its product candidates , the timing and conduct of clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position, and Altamira’s financial position Therapeutics, including the i impact of any future acquisitions, dispositions, partnerships, licensing transactions or capital structure changes, including future securities offerings. These risks and uncertainties also include, but are not limited to, the risks and uncertainties described under the heading “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2021, and in the other Altamira Therapeutics’ filings with the SEC, which are available for free on the Securities Exchange Commission’s website at: If one or more of these risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results could differ materially from those stated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made and Altamira Therapeutics undertakes no obligation to update them in light of new information, future developments or otherwise, except as required under applicable law.


SOURCE: Altamira Therapeutics Ltd.

View the source version at Plaque stability

You might also like